12012 — MIMEDI (Q3698691): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): Recentemente sono emersi medicinali innovativi (medii) al fine di offrire nuove soluzioni terapeutiche ai pazienti con impasse terapeutica. Questi medicinali sono basati sull'uso di cellule "farmaci". Tuttavia, la produzione di questi farmaci richiede l'attuazione di tecnologie complesse e quindi costose. L'ambizione di MiMédi è di razionalizzare la loro produzione fornendo nuove soluzioni tecniche e ottimizzando tutte le fasi necessarie per l...) |
(Removed claim: summary (P836): Innovative (medium) medicines have recently emerged in order to offer new treatment solutions for patients with therapeutic impasses. These medicinal products are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi’s ambition is to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for t...) |
||||||||||||||
| Property / summary | |||||||||||||||
| Property / summary: Innovative (medium) medicines have recently emerged in order to offer new treatment solutions for patients with therapeutic impasses. These medicinal products are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi’s ambition is to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do this, MiMédi combines research laboratories and industry from both engineering and cellular engineering. (English) / rank | |||||||||||||||
| Property / summary: Innovative (medium) medicines have recently emerged in order to offer new treatment solutions for patients with therapeutic impasses. These medicinal products are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi’s ambition is to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do this, MiMédi combines research laboratories and industry from both engineering and cellular engineering. (English) / qualifier | |||||||||||||||
| |||||||||||||||
Revision as of 13:51, 16 May 2022
Project Q3698691 in France
- 12012 – MIMEDI
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 12012 — MIMEDI |
Project Q3698691 in France |
|
Statements
10,211,026.83 Euro
0 references
13,614,711.32 Euro
0 references
75.0 percent
0 references
1 December 2017
0 references
30 November 2021
0 references
Université de Franche-Comté
0 references
47°14'23.03"N, 6°0'44.14"E
0 references
25030
0 references
Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
0 references
0 references
Identifiers
FC0013440
0 references
10341
0 references
4607
0 references